Company / Free Cash Flow
ENANTA PHARMACEUTICALS INC Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$112.2M
FY2025
5-year range
-$112.2M / $66.0M
FY2021-FY2025
Trend
-29.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has declined for 4 consecutive years, from $66M in FY2021 to -$112M in FY2025.
Based on SEC 10-K filings.
-$112M in FY2025.
Declined from -$71M to -$112M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's free cash flow has declined for 4 consecutive years.
- In FY2025, free cash flow decreased 29.1% year-over-year.
- Peak free cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$112.2M | -29.1% |
| FY2024 | -$86.9M | -22.8% |
| FY2023 | -$70.7M | -1353.7% |
| FY2022 | $5.6M | -91.5% |
| FY2021 | $66.0M | +151.5% |
| FY2020 | $26.2M | -47.7% |
| FY2019 | $50.1M | +61.4% |
| FY2018 | $31.1M | -58.2% |
| FY2017 | $74.3M | +288.2% |
| FY2016 | $19.2M | +90.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026